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Phrombopoietin Contributes to Enhanced
latelet Activation in Patients With Unstable Angina
nrico Lupia, MD,* Ornella Bosco, PHD,† Serena Bergerone, MD,‡ Anna Erna Dondi, MD,†
lberto Goffi, MD,† Elena Oliaro, MD,‡ Marco Cordero, MD,‡ Lorenzo Del Sorbo, MD,†
iampaolo Trevi, MD,‡ Giuseppe Montrucchio, MD†
urin, Italy
OBJECTIVES We sought to investigate the potential role of elevated levels of thrombopoietin (TPO) in
platelet activation during unstable angina (UA).
BACKGROUND Thrombopoietin is a humoral growth factor that does not induce platelet aggregation per se,
but primes platelet activation in response to several agonists. No data concerning its
contribution to platelet function abnormalities described in patients with UA are available.
METHODS We studied 15 patients with UA and, as controls, 15 patients with stable angina (SA) and 15
healthy subjects. We measured TPO and C-reactive protein (CRP), as well as monocyte-
platelet binding and the platelet expression of P-selectin and of the TPO receptor, c-Mpl.
The priming activity of patient or control plasma on platelet aggregation and monocyte-
platelet binding and the role of TPO in this effect also were studied.
RESULTS Patients with UA showed higher circulating TPO levels, as well as increased monocyte-
platelet binding, platelet P-selectin expression, and CRP levels, than those with SA and
healthy control subjects. The UA patients also showed reduced platelet expression of the
TPO receptor, c-Mpl. In vitro, the plasma from UA patients, but not from SA patients or
healthy controls, primed platelet aggregation and monocyte-platelet binding, which were
both reduced when an inhibitor of TPO was used.
CONCLUSIONS Thrombopoietin may enhance platelet activation in the early phases of UA, potentially
participating in the pathogenesis of acute coronary syndromes. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.1062195–203) © 2006 by the American College of Cardiology Foundation
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patients with unstable angina (UA) have hypersensitive
latelets, circulating platelet aggregates, and elevated levels
f circulating platelet secretory products (1–5). They also
how increased platelet-leukocyte aggregates, which have
een proposed to represent a better reflection of plaque
nstability and ongoing vascular thrombosis and inflamma-
ion (6,7). Indeed, activated platelets deposit at sites of
nstable plaque rupture and may potentiate thrombus for-
ation, precipitating or exacerbating coronary vascular ob-
truction (3). The clinical efficacy of antiplatelet therapies
lso confirms the importance of platelets in acute coronary
yndromes (8); however, their incomplete effectiveness sug-
ests alternative platelet activation pathways may be impor-
ant (8).
Thrombopoietin (TPO) is a humoral growth factor
riginally identified using antisense oligonucleotides to
-Mpl (9), a protooncogene described by Wendling et al.
10) in 1986, and characterized for its ability to stimulate
he proliferation and differentiation of megakaryocytes
11–14). Thrombopoietin is constitutively produced by
he liver and kidneys and is then cleared from circulation
pon binding with its receptor, c-Mpl, expressed mainly
From the *Azienda Ospedaliera San Giovanni Battista-Molinette, Turin, Italy; and
he †Department of Clinical Pathophysiology and ‡Department of Internal Medi-
ine, University of Turin, Turin, Italy. Dr. Montrucchio was supported by Murst
x-60%, Murst Cofin 2002, FIRB 2001, and Progetto di Ricerca Sanitaria Finaliz-
ata–Regione Piemonte 2004. Drs. Lupia and Bosco contributed equally to this work.e
Manuscript received January 24, 2006; revised manuscript received April 14, 2006,
ccepted April 17, 2006.n platelets and megakaryocytes (15,16). Elevated plasma
PO levels have been reported in different clinical
onditions, including hematologic diseases, where in-
reased circulating TPO may be a response to altered
one marrow hemopoiesis (17–19) and sepsis (20).
oreover, higher levels of TPO have been found in
atients with acute coronary syndromes than in control
ubjects and shown to correlate with platelet size, thus
otentially resulting in hemostatically more active plate-
ets (21). We and others have shown that TPO directly
odulates the response of mature platelets to several
timuli and thereby their homeostatic potential (22,23).
n particular, TPO, which does not induce platelet
ggregation per se, enhances platelet activation in re-
ponse to several agonists (22,23) and the subsequent
latelet/leukocyte adhesion via P-selectin (24).
The aim of the present study was to investigate the
otential pathogenic role of elevated levels of TPO in
ustaining platelet aggregation and monocyte-platelet inter-
ction in UA patients. We measured TPO levels in patients
ith unstable and stable angina (SA) and healthy controls
nd found that patients with UA showed higher circulating
PO levels than those with SA and healthy controls, as well
s increased markers of platelet activation in vivo. In
ddition, we showed that plasma from patients with UA,
ut not from patients with SA or healthy controls, primes
latelet activation in vitro and that TPO has a role in this
ffect.
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atients. The study group comprised 15 patients with UA
ho had ischemic chest pain at rest with transient ST-
egment depression and/or T-wave inversion (Braunwald
lass IIIB [25]) within the preceding 8 h, 15 SA patients,
nd 15 subjects without clinical evidence of coronary ath-
rosclerosis used for controls. The SA patients had stable
ffort angina (Canadian Cardiovascular Society class II to
II), a positive exercise test, and angiographically docu-
ented coronary atherosclerotic lesions. The UA patients
ere enrolled at the time of hospital admission, and blood
ampling was performed in the emergency room before any
herapeutic intervention was started. Exclusion criteria were
dvanced kidney or liver failure, overt heart failure, known
ardiomyopathy or hemodynamically significant valvular
eart disease, known hematologic disease affecting coagu-
ation, platelet, or TPO production (16–18,26), known
alignancies, inflammatory diseases, and major surgery (27)
r trauma within the preceding month. We considered
atients who were receiving dietary treatment or medication
or diabetes or whose fasting blood glucose level was above
26 mg/dl twice to have diabetes mellitus. Angiographically
evere coronary artery disease was defined by the presence of
or more stenoses of at least 70% in any major coronary
rtery. The study was approved by the hospital ethics
ommittee and conducted according to the Helsinki Dec-
aration. All subjects gave informed consent.
Clean venipunctures were performed by trained investi-
ators using 19-gauge butterfly infusion sets without venous
tasis. After discarding the first 4 ml, blood entered Vacu-
ainers (Becton Dickinson, Franklin Lakes, New Jersey)
ontaining EDTA or 3.8% trisodium citrate as appropriate.
o obtain plasma samples, EDTA-anticoagulated tubes
ere centrifuged at 1,600 g for 10 min at 4°C. Plasma was
hen centrifuged again at 12,500 g for 10 min at 4°C, filtered
hrough 0.22 m pores, and immediately frozen and stored
t 70°C.
iochemical analyses. The TPO levels in plasma were
easured using an enzyme-linked immunosorbent assay
R&D Systems, Minneapolis, Minnesota) following the
anufacturer’s instructions. C-reactive protein (CRP) was
ssayed by high-sensitivity nephelometry (Dade Behring,
Abbreviations and Acronyms
ADP  adenosine 5=-diphosphate
CRP  C-reactive protein
EPI  epinephrine
PI  priming index
PRP  platelet-rich plasma
rhTPO  recombinant human thrombopoietin
SA  stable angina
TPO  thrombopoietin
TPOR  thrombopoietin receptor
UA  unstable anginaarburg, Germany). glow cytometry. Leucocyte-platelet aggregates in vivo
ere analyzed by 3-color staining of whole blood samples,
s previously described (28). Briefly, blood was collected,
iluted 1:1 with Tyrodes’ HEPES-buffered saline (pH 7.4),
nd added to a mixture of fluorescein isothiocyanate
FITC)-conjugated anti-CD45 (Beckman Coulter, Miami,
lorida), energy coupled dye-conjugated anti-CD14 (Beck-
an Coulter, Marseille, France), and phycoerythrin-
onjugated anti-CD41 (Dako Cytomation, Glostrup, Den-
ark) monoclonal antibodies, and incubated 15 min at
oom temperature. Cells were then fixed with 1% parafor-
aldehyde, and erythrocytes were removed by hypotonic
ysis. Samples were washed twice with phosphate-buffered
aline (PBS)–bovine serum albumin 0.1% and resuspended
n 0.5 ml PBS.
Samples were analyzed on an EPICS-XL flow cytometer
Coulter, Hialeah, Florida). Gates were set during analysis
n the ground of CD45 versus CD14 expression using a
ogical gate to discriminate lymphocyte, polymorphonu-
lear, and monocyte populations. The percentage of leuko-
yte subgroups coexpressing CD45-CD41 or CD14-CD41
ver the total population of leukocytes expressing CD45 or
D14 was used as an index of platelet-leukocyte adhesion
29).
For in vitro experiments, 100 l diluted blood from
ealthy adult donors was preincubated at 37°C with 25 l
lasma from patients or control subjects or recombinant
uman TPO (rhTPO) (R&D Systems) for 5 min and then
timulated with adenosine 5=-diphosphate (ADP) (0.8
mol/l; Helena Laboratories, Beaumont, Texas) or epi-
ephrine (EPI) (3 mol/l; Helena Laboratories). Samples
ere then processed and analyzed as described in the
receding text.
In separate experiments, plasma or rhTPO was incubated
ith a human TPO receptor (TPOR)–Fc chimera (2.5
g/ml; R&D Systems) for 5 min at 37°C; the mixture of
ample and TPOR-Fc chimera was added to whole blood,
urther incubated for 5 min at 37°C, and stimulated with
DP or EPI.
P-selectin expression was evaluated in whole blood using
n FITC-conjugated anti–P-selectin monoclonal antibody
rom Ancell Corporation (Bayport, Minnesota). Platelet
-Mpl surface expression was examined in fixed platelet-rich
lasma (PRP) using an anti–c-Mpl monoclonal antibody
R&D Systems) followed by Alexa Fluor 488–conjugated
ntimouse immunoglobulin G monoclonal antibody (Mo-
ecular Probes, Eugene, Oregon).
latelet aggregation. Platelet aggregation in PRP and
hole blood was evaluated as previously described (22,28).
latelet-rich plasma or whole blood was obtained from
ealthy subjects as described in the preceding and incubated
ith 25 to 100 l plasma or rhTPO at 37°C. When
valuating priming activity, ADP or EPI was added as
econdary agonist. For each experiment, the ADP or EPI
oncentration that induced the minimum measurable aggre-
ation was determined; ADP dose range was 0.8 to 2
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December 5, 2006:2195–203 TPO and Platelet Activation in UAmol/l; EPI dose range was 0.1 to 3 mol/l. The priming
ndex (PI) was calculated as the response to plasma or
hTPO and agonist together, divided by the sum of indi-
idual responses elicited by plasma or rhTPO and agonist
22,28).
In separate experiments, plasma or rhTPO was incubated
ith the TPOR-Fc chimera (2.5 g/ml) for 5 min at 37°C;
he mixture of sample and TPOR-Fc chimera was added to
RP or whole blood, further incubated for 5 min at 37°C,
nd stimulated with ADP or EPI.
In selected experiments, PRP was preincubated with
cetylsalicylic acid (0.1 mmol/l; Sigma Chemical Co., St.
ouis, Missouri) for 30 min at 37°C before stimulation with
lasma or rhTPO, followed by ADP or EPI.
yrosine phosphorylation of c-Mpl. In some experi-
ents, PRP was prepared from patients or controls,
timulated with rhTPO (100 ng/ml) for 10 min, and then
ysed in lysis buffer (20 mmol/l Tris-HCl, pH 7.4, 150
mol/l NaCl, 1% Nonidet P-40) containing protease and
hosphatase inhibitors. Immunoprecipitation was per-
ormed using a rabbit polyclonal antibody anti– c-Mpl
Upstate Biotechnology, Lake Placid, New York). After
DS-PAGE, immunoprecipitated proteins were trans-
Table 1. Characteristics of the Patients*
Characteristics
Healthy
(n 
Age, yrs 66.3
Gender, n
Male 9
Female 6
Risk factors, n (%)
Family history 3
Hypertension 5
Current smoking 4
Hypercholesterolemia 2
Diabetes 0
Therapy (at the time of hospital
presentation), n (%)
Anti-platelet
ASA 0
Ticlopidine 0
Clopidogrel 0
Beta-blockers 2
ACE inhibitors/ARBs 5
Nitrates 0
Statins 0
Calcium-channel blockers 0
Angiographic findings
1-vessel disease n.
2-vessel disease n.
3-vessel disease n.
Platelets (109/l) 200.8
MPV (fl) 10.8
WBC (106/l) 6,605.4
Monocytes (106/l) 400.1
*Plus-minus values are mean  SE. †p  0.05 for the comp
ACE  angiotensin-converting enzyme; ARB  angiote
platelet volume; n.d.  not determined; SA  stable anginaered to nitrocellulose membranes and blotted with anti- chosphotyrosine monoclonal antibody PY20 (Sigma
hemical Co.).
tatistical analysis. Values are represented by mean  SE.
omparisons between groups were analyzed by 1-way
nalysis of variance followed by Newman-Keuls multicom-
arison test; categoric variables were compared by 2-way
ross-tabulation with the chi-square test. A p value of
0.05 was considered significant.
ESULTS
atient clinical characteristics and TPO levels. Table 1
ives demographic and clinical data for patients and con-
rols. The UA and SA patients did not differ regarding
emographic and baseline clinical characteristics or treat-
ent. Platelet, leukocyte, and monocyte counts were not
ignificantly different in the 3 groups and neither was mean
latelet volume. In contrast, plasma TPO concentrations
ere significantly higher in patients with UA than in those
ith SA or in healthy control subjects (Fig. 1A). The CRP
alues were also significantly higher in UA (5.23  1.31
g/l) than in SA (2.19  0.41 mg/l) patients or in healthy
rols SA Patients
(n  15)
UA Patients
(n  15)
65.5  3.4 68.0  2.2
12 10
3 5
5 (33.3) 5 (33.3)
† 13 (86.7) 14 (93.3)
3 (20.0) 1 (6.7)
† 15 (100.0) 14 (93.3)
5 (33.3) 5 (33.3)
13 (86.7) 15 (100.0)
2 (13.3) 1 (6.7)
1 (6.7) 1 (6.7)
† 10 (66.7) 12 (80.0)
6 (40.0) 8 (53.3)
8 (53.3) 10 (66.7)
8 (53.3) 10 (66.7)
5 (33.3) 4 (26.7)
1 (6.7) 1 (6.7)
5 (33.3) 4 (26.7)
9 (60.0) 10 (66.7)
.9 202.1  13.2 205.5  14.1
10.9  0.4 11.7  0.4
6.0 6,808.0  688.4 6,397.1  254.4
.8 358.0  52.4 426.0  67.8
with the other 2 groups.
eceptor blocker; ASA  acetylsalicylic acid; MPV  mean
 unstable angina; WBC  white blood cells.Cont
15)
 3.4
(20.0)
(33.3)
(26.7)
(13.3)
†
†
(13.3)
(33.3)
†
†
†
d.
d.
d.
 11
 0.2
 70
 35
arison
nsin r
; UAontrol subjects (1.83  0.54 mg/l).
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TPO and Platelet Activation in UA December 5, 2006:2195–203n vivo platelet activation in patients with UA. Signifi-
antly higher percentages of monocyte-platelet binding
ere found in unstable than in SA patients or healthy
ontrols (Fig. 1B). The percentage of platelets expressing
-selectin was also significantly higher in unstable than in
A patients or healthy controls (Fig. 1C).
ecreased platelet expression of c-Mpl in UA patients.
ecause c-Mpl expression is down-regulated following in-
ernalization upon TPO binding (30,31), we examined
latelet c-Mpl expression as an indirect marker of in vivo
latelet activation by circulating endogenous TPO. The
igure 1. (A) Plasma thrombopoietin (TPO) levels in healthy control subj
onocyte-platelet aggregates and (C) platelet P-selectin expression detecte
nd UA. One-way analysis of variance with Newman-Keuls multicompari
igure 2. (A) Representative fluorescence-activated cell sorting (FACS) an
n vivo in healthy control subjects (C) and in patients with stable angina (
inding of non-specific antimouse immunoglobulin G monoclonal antib
onoclonal antibody. (B) Quantification of c-Mpl expression on platelet s
ACS analysis. One-way analysis of variance with Newman-Keuls multic
hosphorylation state of c-Mpl in platelet lysates from healthy control subje
ere either unstimulated or stimulated with saturating concentrations of recom
n platelets from SA patients and healthy control subjects but not in platelets from U-Mpl expression was markedly lower in UA than in SA
atients or in healthy control subjects (Figs. 2A and 2B).
When we examined the phosphorylation state of c-Mpl
eceptor in platelets stimulated in vitro with saturating
hTPO levels, we found that c-Mpl was phosphorylated in
latelets from SA patients and healthy control subjects but
ot in platelets from UA patients, showing that in UA
atients the receptor was functionally non-responding to
PO stimulation in vitro (Fig. 2C).
Finally, rhTPO did not enhance the aggregation induced
y ADP or EPI in PRP from patients with UA, whereas it
C) and in patients with stable angina (SA) and unstable angina (UA). (B)
ivo, by flow cytometry, in healthy control subjects and in patients with SA
est was performed.
showing the percentage of c-Mpl expression on platelet surface detected
nd unstable angina (UA). The solid curve represents fluorescence due to
the open curve represents fluorescence due to binding of anti–c-Mpl
e detected in vivo in healthy controls and in patients with SA and UA by
ison test was performed. (C) Representative Western blot analysis of the
d from patients with SA and UA. Platelets from control subjects or patientsects (
d in valysis
SA) a
ody;
urfac
ompar
cts anbinant human thrombopoietin (rhTPO). The c-Mpl was phosphorylated
A patients. Shown is a representative experiment out of 4 with similar results.
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December 5, 2006:2195–203 TPO and Platelet Activation in UArimed platelet aggregation in PRP from patients with SA
nd from healthy control subjects (data not shown). This
uggests that increased TPO levels in vivo may account for
he reduced reactivity to rhTPO in vitro in PRP from
atients with UA.
lasma of UA patients primed platelet activation in
itro. The effect of plasma samples from patients or con-
rols on platelet aggregation was tested in vitro on PRP or
hole blood obtained from healthy donors. Plasma from
A patients per se did not induce platelet aggregation, but
t significantly enhanced aggregation induced by low ADP
r EPI concentrations in PRP (Figs. 3A and 3B). All
lasma samples examined induced this priming effect on
latelet aggregation in PRP. Also in whole blood, preincu-
ation of samples with plasma from UA patients primed
ggregation induced by ADP or EPI (Figs. 3C and 3D).
he priming effect of plasma samples from UA patients was
vident after 5 min of incubation with PRP or whole blood
nd persisted up to 60 min. Moreover, it was still significant
fter pretreatment of PRP with acetylsalicylic acid (0.1
mol/l), which partially reduced ADP-induced platelet
ggregation (from 2.40  0.50 to 1.77  0.31) and
nhibited the secondary phase of EPI-induced platelet
ggregation (from 2.30  0.02 to 1.72  0.04). Finally,
lasma of UA patients also induced a significant, although
eaker, priming effect in PRP from healthy subjects after 1
eek of oral treatment with acetylsalicylic acid (100 mg/
igure 3. Representative aggregation traces and quantification of the in v
atients with stable angina (SA) and unstable angina (UA) on (A) adenosin
n PRP. Representative aggregation traces and quantification of the in vitro
nd UA on (C) ADP- or (D) EPI-induced platelet aggregation in whole
as performed.ay) (data not shown). Plasma from SA patients or healthy wontrol subjects did not prime platelet aggregation in PRP
or in whole blood (Fig. 3).
In parallel experiments, we used rhTPO to investigate the
ose range needed to induce a priming effect on platelet
ggregation. Alone, rhTPO (from 20 pg/ml to 80 ng/ml)
id not induce platelet aggregation in PRP nor in whole
lood but enhanced platelet aggregation when administered
efore ADP or EPI. The minimal “priming” dose of rhTPO
as 20 pg/ml in PRP and 50 pg/ml in whole blood. These
oncentrations are similar to those detected in vivo in the
irculation of UA patients. No priming effect on ADP- or
PI-induced platelet aggregation was seen using
nterleukin-6, interleukin-3, granulocyte colony-stimulating
actor, or granulocyte-macrophage colony-stimulating fac-
or (data not shown).
Plasma from UA patients, but not from SA patients or
ealthy control subjects, also significantly enhanced
onocyte-platelet binding and P-selectin expression in
hole blood (Fig. 4).
ole of TPO in the priming activity of plasma from UA
atients. We hypothesized that the soluble plasmatic factor
esponsible for the effect of plasma from patients with UA
n platelet aggregation and monocyte-platelet binding
ould be TPO. To test this hypothesis, the contribution of
PO to platelet activation was assessed by using a human
POR-Fc chimera, which inhibits the proliferation induced
y rhTPO on MO7e cells (32). In preliminary experiments,
riming activity induced by plasma from healthy control subjects (C) and
iphosphate (ADP)- or (B) epinephrine (EPI)-induced platelet aggregation
ing activity induced by plasma from healthy controls and patients with SA
. One-way analysis of variance with Newman-Keuls multicomparison testitro p
e 5=-d
prime found that the TPOR-Fc chimera, at a concentration of
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and platelet P-selectin expression were analyzed by flow cytometry. Analysis of
variance with Newman-Keuls multicomparison test was performed.
F
i
a
induced by plasma from UA patients on (C) ADP- or (D) EPI-induced p
Newman-Keuls multicomparison test was performed.
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TPO and Platelet Activation in UA December 5, 2006:2195–203.5 g/ml, inhibited the priming effect exerted by rhTPO in
RP but did not affect the aggregation induced by ADP or
PI. Pretreatment of plasma sample with the TPOR-Fc
himera reduced by about 80% the priming effect exerted by
lasma from UA patients on platelet aggregation in both
RP (Figs. 5A and 5B) and whole blood (Figs. 5C and 5D).
t also significantly decreased monocyte-platelet binding
nd P-selectin expression observed after preincubation of
he sample with plasma from UA patients (Fig. 6). In
ontrast, preincubation of plasma from SA patients or
ealthy control subjects with the TPOR-Fc chimera had no
ffect (data not shown).
Finally, we adjusted the concentrations of TPO in plasma
rom SA patients to those measured in UA patients by
dding exogenous rhTPO. After addition of rhTPO,
lasma from SA patients, which did not show priming
ctivity per se, was able to induce a significant priming
ffect, similar to that observed with plasma from patients
ith UA, on ADP- or EPI-induced aggregation in PRP (PI
1.89  0.15 on ADP-induced aggregation, p  0.01;
.45  0.34 on EPI-induced aggregation, p  0.05).
ISCUSSION
he present study demonstrates the importance of TPO
n the pathophysiology of increased platelet activation
uring UA. We showed indeed that patients with UA
ave high circulating TPO levels together with increased
onocyte-platelet binding and platelet P-selectin expres-
ombopoietin receptor (TPOR)-Fc chimera on the in vitro priming activity
ine 5=-diphosphate (ADP)- or (B) epinephrine (EPI)-induced platelet
fication of the effect of TPOR-Fc chimera on the in vitro priming activityigure 4. (A) In vitro effect of plasma from healthy control subjects (C)
nd patients with stable angina (SA) and unstable angina (UA) on
denosine 5=-diphosphate-induced monocyte-platelet aggregation (left)
nd platelet P-selectin expression (right) in whole blood. (B) In vitro effect
f plasma from healthy control subjects and patients with SA and UA on
pinephrine-induced monocyte-platelet aggregation (left) and platelet
-selectin expression (right) in whole blood. Monocyte-platelet aggregatesigure 5. Representative aggregation traces and quantification of the effect of thr
nduced by plasma from patients with unstable angina (UA) on (A) adenos
ggregation in platelet-rich plasma. Representative aggregation traces and quantilatelet aggregation in whole blood. One-way analysis of variance with
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December 5, 2006:2195–203 TPO and Platelet Activation in UAion in vivo, and that TPO present in the plasma of
atients with UA may have a pathogenic role in this
ondition by priming platelet aggregation and monocyte-
latelet interaction.
Confirming what was previously reported by Senaran et
l. (21), we found higher circulating TPO levels in patients
ith UA, at the time of hospital admission, than in
atients with SA or in healthy control subjects. However,
hereas that earlier study was conducted within 12 h
fter hospital admission (21) (i.e., when several clinical
actors and therapeutic interventions may have already
ntervened), we enrolled the UA patients in the emer-
ency room before any therapeutic intervention was
tarted. Therefore, we believe that our data may more
losely reflect the ongoing pathogenic events leading to
he development of UA.
Patients with UA also showed reduced surface expression
f c-Mpl on circulating platelets, whereas no such a change
as detected in patients with SA or healthy controls.
eceptor-mediated internalization is considered the pri-
ary means of regulating plasma TPO levels (30,31).
iminished c-Mpl expression in platelets from UA patients
ay therefore depend on the previous binding of TPO to its
eceptor in vivo, followed by its internalization and surface
own-regulation (30,31). In addition, rhTPO is able to
igure 6. (A) Effect of thrombopoietin receptor (TPOR)-Fc chimera on
he priming activity induced by plasma from patients with unstable angina
UA) on adenosine 5=-diphosphate (ADP)-induced monocyte-platelet
ggregation (left) and platelet P-selectin expression (right) in whole blood.
B) Effect of TPOR-Fc chimera on the priming activity induced by plasma
rom patients with UA on epinephrine (EPI)-induced monocyte-platelet
ggregation (left) and platelet P-selectin expression (right) in whole blood.
retreatment of plasma sample with the TPOR-Fc chimera significantly
educed the percentages of ADP- or EPI-induced monocyte-platelet binding
nd platelet P-selectin expression observed after preincubation of whole
lood from healthy adult donors with plasma from UA patients. Analysis
f variance with Newman-Keuls multicomparison test was performed.hosphorylate c-Mpl only in platelets from SA patients and aealthy control subjects but not in those from UA patients,
urther supporting this hypothesis. Platelets from patients
ith UA also showed reduced reactivity to rhTPO ex vivo,
ossibly related to their exposure in vivo to increased levels
f endogenous TPO, analogously to what was previously
hown for thrombocytopenic mice (33) and humans with
he syndrome of congenital thrombocytopenia with absent
adii (33,34).
In addition to elevated plasmatic concentrations of TPO,
atients with UA also showed increased indexes of in vivo
latelet activation, such as monocyte-platelet binding and
latelet P-selectin expression. It is well known that platelet
ctivation occurs during the early phases of UA (1–6,8) and
hat monocyte-platelet aggregation is not only a sensitive
easure of platelet activation but also has significant proin-
ammatory consequences (6,7,35,36). Thus, our in vivo and
n vitro findings suggest an important link between circu-
ating TPO level and the proinflammatory and prothrom-
otic state that occurs in UA patients.
The precise origin of the rise in plasma TPO level in UA
atients remains unclear. We found that CRP levels were
ncreased in this study group, suggesting that the liver
cute-phase response, which takes place in acute coronary
yndromes (37–39), may have a role in increasing TPO
evels. Considering the evidence that elevated CRP has
ndependent prognostic value in UA (40,41), it is tempting
o speculate that the negative prognostic implications of
igh CRP levels in patients with UA may be at least
artially related to the concomitant increase in TPO pro-
uction and subsequent priming of platelet aggregation.
owever, activated platelets could also represent a major
ontributor to the elevated TPO levels observed in UA
atients, because they are known to release full-length
iologically active TPO upon stimulation (26).
In vitro, plasma from patients with UA, but not from SA
atients or healthy control subjects, markedly enhances
latelet aggregation as well as monocyte-platelet binding in
lood samples from healthy donors, stressing the impor-
ance of elevated TPO concentrations in the pathogenesis of
ncreased platelet aggregation in UA. Several aspects of the
ata show that the priming effect exerted by plasma samples
rom patients with UA may be due to their content in TPO:
) the priming effect induced by plasma from UA patients
as significantly decreased when TPO activity was inhibited
ith a TPOR-Fc chimera; and 2) adjusting the concentra-
ions of TPO in plasma from SA patients to those measured
n UA patients by adding exogenous rhTPO induced a
ignificant increase of the priming effect, similar to that
bserved with plasma from patients with UA, on ADP- or
PI-induced aggregation in PRP. In vivo, a similar priming
ffect induced by TPO on platelet activation has been
ocumented in non-human primates; platelets derived from
PO-treated animals showed a heightened sensitivity to
ubstances that stimulate platelet aggregation during the
rst few days of treatment (42). No priming effect on ADP-
nd EPI-induced platelet aggregation in both PRP and
w
g
m
u
a
p
a
w
s
o
u
p
l
o
p
a
s
c
m
T
c
c
R
c
S
g
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
2202 Lupia et al. JACC Vol. 48, No. 11, 2006
TPO and Platelet Activation in UA December 5, 2006:2195–203hole blood was seen using interleukin-6, interleukin-3,
ranulocyte colony-stimulating factor, or granulocyte-
acrophage colony-stimulating factor; however, other sol-
ble mediators released during UA have been shown to
ffect platelet function (43,44).
Plasma from UA patients also induced a significant
riming effect on platelet aggregation in the presence of
cetylsalicylic acid or in PRP from healthy subjects after 1
eek of oral acetylsalicylic acid treatment. These results
uggest that the activation pathway triggered by TPO is
nly partially affected by the anti-platelet therapy commonly
sed in patients with myocardial ischemia (8) and that
latelet priming by TPO may represent a mechanism
eading to therapeutic failure of anti-platelet agents. More-
ver, the phenomenon we described in this study may
rovide the rationale for more aggressive (double or triple)
nti-platelet treatment in patients with acute coronary
yndromes.
In conclusion, we have shown that elevated levels of
irculating TPO may enhance platelet activation and
onocyte-platelet interaction in the early phases of UA.
hese findings implicate TPO in the pathogenesis of acute
oronary syndromes, where it could potentially precipitate
onditions of clinical instability.
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